A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium

Kathleen N Moore,Michael W Sill,M Tenney,Christopher J Darus, David Griffin,Theresa L Werner,Peter G Rose,Robert Behrens

Gynecologic Oncology（2015）

引用 31|浏览8

暂无评分

摘要

•Angiogenesis is a rationale target in endometrial cancer•Trebananib works through VEGF independent pathways to target angiogenesis•Trebananib did not meet response endpoints in this trial

查看译文

关键词

Endometrial cancer,Angiogenesis,Trebananib,NCT01210222

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要